Apricus Biosciences to Present at the 2017 BIO Investor Forum

SAN DIEGO, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. APRI, a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Richard Pascoe, Chief Executive Officer, will present at the 2017 BIO Investor Forum on Wednesday, October 18, 2017, at 9:00 a.m. Pacific Time.  The conference will be held at The Westin St. Francis Hotel in San Francisco, CA.  Mr. Pascoe will provide an update on the Company's strategy and plans surrounding Vitaros™.

A live audio webcast of the presentation can be accessed via the Investor Relations' section of the Company's website at www.apricusbio.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros™ is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros^® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa™ is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

CONTACT:    Matthew Beck

                      mbeck@troutgroup.com

                      The Trout Group

                      (646) 378-2933